VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/32343948/

⇱ IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study - PubMed

Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
👁 Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

👁 Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

Validation studies of serological antibody tests must be properly designed for clinical, epidemiological and Public Health objectives such as confirmation of suspected COVID-19 cases, certification of seroconversion after infection, and epidemiological surveillance. We evaluated the kinetics of IgM, IgA and IgG SARS-CoV-2 antibodies in COVID-19 patients with confirmed (rRT-PCR) infection. We found that the IgA response appears and grows early, peaks at week 3, and it is stronger and more persistent than the IgM response. Further longitudinal investigations of virus-specific antibodies functions and of their protective efficacy over time are needed.

PubMed Disclaimer

Figures

👁 Fig. 1
Fig. 1
Kinetics of IgA (ELISA) and IgM (CLIA) of patients monitored from the onset of symptoms (fever).
👁 Fig. 2
Fig. 2
Spaghetti plot of patients with more than 3 serial antibody determinations after the onset of symptoms (fever): A) IgA (n = 17 patients); B) IgM (n = 18 patients).
👁 Supplementary figure 1
Supplementary figure 1

References

    1. Mizumoto K., Kagaya K., Zarebski A., Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10) doi: 10.2807/1560-7917. - DOI - PMC - PubMed
    1. T.F. Amana, T.H.O. Nguyen, V. Chromikova, S. Strohmeier, D. Stadblauer, Javier A et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv http://doi.org/10.1101/2020.03.17.20037713. - PMC - PubMed
    1. Okba Nisreen M.A., Müller Marcel A., Li Wentao, Wang Chunyan, GeurtsvanKessel Corine H., Corman Victor M., Lamers Mart M., Sikkema Reina S., de Bruin Erwin, Chandler Felicity D., Yazdanpanah Yazdan, Le Hingrat Quentin, Descamps Diane, Houhou-Fidouh Nadhira, Reusken Chantal B.E.M., Bosch Berend-Jan, Drosten Christian, Koopmans Marion P.G., Haagmans Bart L. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients. Emerg. Infect. Dis. 2020;26(7) doi: 10.3201/eid2607.200841. - DOI - PMC - PubMed
    1. A. Padoan, C. Cosma, L. Sciacovelli, D. Faggian, M. Plebani, Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin. Chem. Lab. Med. 2020 Apr 16. pii:/j/cclm.ahead-of-print/cclm-2020-0443/cclm-2020-0443.xml. http://doi.org/10.1515/cclm-2020-0443. [Epub ahead of print]. - PubMed
    1. R. Lassauniere, A. Frische, Z.B. Harboe, A.C.Y. Nielsen, A. Fomsgaard, K.A. Krogfelt et al. Evaluation of nine commercial SARS-CoV-2 immunoassays, medrxv http://doi.org/10.1101/2020.04.09.20056325.

MeSH terms

Substances

LinkOut - more resources

Full text links
👁 Elsevier Science full text link
Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.